Loading…
Zeuss LLC was cited for misbranding compounded tirzepatide drug products through false or misleading claims on its website in violation of the Federal Food, Drug, and Cosmetic Act. The company falsely represented itself as the compounder of the drugs and made unsubstantiated claims that the products were FDA-approved, clinically proven for weight loss, and rigorously tested for safety and efficacy—statements that are prohibited for non-FDA-approved compounded drugs. These violations resulted in the misbranded products being introduced into interstate commerce without proper compliance with FDA regulations governing drug labeling and advertising.